261 related articles for article (PubMed ID: 26831100)
1. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
[TBL] [Abstract][Full Text] [Related]
2. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
3. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
4. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
Haderski GJ; Kandar BM; Brackett CM; Toshkov IM; Johnson CP; Paszkiewicz GM; Natarajan V; Gleiberman AS; Gudkov AV; Burdelya LG
PLoS One; 2020; 15(2):e0227940. PubMed ID: 32027657
[TBL] [Abstract][Full Text] [Related]
5. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
[TBL] [Abstract][Full Text] [Related]
6. Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver.
Miyagi T; Takehara T; Tatsumi T; Suzuki T; Jinushi M; Kanazawa Y; Hiramatsu N; Kanto T; Tsuji S; Hori M; Hayashi N
Hepatology; 2004 Nov; 40(5):1190-6. PubMed ID: 15486936
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
8. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.
Choi BK; Kim YH; Kim CH; Kim MS; Kim KH; Oh HS; Lee MJ; Lee DK; Vinay DS; Kwon BS
J Immunol; 2010 Aug; 185(3):1404-11. PubMed ID: 20610645
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
11. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
[TBL] [Abstract][Full Text] [Related]
12. A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications.
Mett V; Kurnasov OV; Bespalov IA; Molodtsov I; Brackett CM; Burdelya LG; Purmal AA; Gleiberman AS; Toshkov IA; Burkhart CA; Kogan YN; Andrianova EL; Gudkov AV; Osterman AL
Commun Biol; 2021 Apr; 4(1):466. PubMed ID: 33846531
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
Kojouharov BM; Brackett CM; Veith JM; Johnson CP; Gitlin II; Toshkov IA; Gleiberman AS; Gudkov AV; Burdelya LG
Oncotarget; 2014 Feb; 5(3):802-14. PubMed ID: 24583651
[TBL] [Abstract][Full Text] [Related]
14. Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.
Yang F; Kosten TR
Psychopharmacology (Berl); 2019 Oct; 236(10):2899-2907. PubMed ID: 30726515
[TBL] [Abstract][Full Text] [Related]
15. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma.
Jovanovic I; Radosavljevic G; Mitrovic M; Juranic VL; McKenzie AN; Arsenijevic N; Jonjic S; Lukic ML
Eur J Immunol; 2011 Jul; 41(7):1902-12. PubMed ID: 21484786
[TBL] [Abstract][Full Text] [Related]
16. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.
Hossain MS; Ramachandiran S; Gewirtz AT; Waller EK
PLoS One; 2014; 9(5):e96165. PubMed ID: 24879439
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
18. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
[TBL] [Abstract][Full Text] [Related]
19. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]